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ABSTRACT
Objective: The purpose of this case study is to inform athletic trainers of a systematic disease
not common in our patient population. Background: The athlete, a twenty-one YO, 160 lb, 69
inch female NCAA-I collegiate soccer goalie presented with complaint of bilateral elbow and
knee joint pain and stiffness along with tender red itchy bumps on the anterior aspect of her
shins. The athlete had flu-like symptoms and a URI prior to this complaint. The athlete has a
history of anemia, mononucleosis, and streptococcal. Differential Diagnosis: Rheumatoid
arthritis, lymphoma, HIV/aids, erythema nodosum, lupus, Lyme disease. Treatment: The athlete
sought out multiple medical evaluations to treat the condition; including the ER. Multiple tests
were run to rule out strep among other things. The athlete received various prescriptions to treat
fatigue, infection, inflammation, and pain. Uniqueness: Erythema nodosum is a rare disorder
that affects approximately 1-5 per 100,000 people per year. Typically seen in the female 25-40
year old population, the cause is usually idiopathic; however, the most common cause is
streptococcal pharyngitis.1-6 Conclusion: This case demonstrates the awareness of a systematic
condition that could be present within the athletic population. With this information, clinicians
can better diagnose and treat erythema nodosum along with awareness of etiologies causing the
condition. Key Words: Erythema nodosum
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CHAPTER 1
INTRODUCTION
Erythema nodosum (EN) is a common type of septal panniculitis that occurs when the
hypodermal septa becomes inflamed with neutrophils.1 Due to a reactive process the septa in
subcutaneous fat filters with inflammatory cells and produces reactive oxygen causing localized
edema.1-6 This hypersensitive response can be caused by varying antigens, but in 1/3 of all cases
is reported as idiopathic.7,8 Most commonly seen in females, in 83% of cases, during their
twenties to forties, EN presents as round red tender nodules bilaterally on the anterior tibia.3
Nodules generally resolve within 4-6 weeks after onset without signs of scarring, atrophy, or
ulceration.7,8
Association with infections, drugs, chronic inflammatory diseases, malignancy, and a
number of disease processes can cause the sudden acute onset of EN.3,6-8 Patients may present
with fever, chills, malaise, arthralgia, and arthritis in conjunction with anterior tibia nodules.4,6,9
Diagnostic testing can consist of a complete blood count (CBC), erythrocyte sedimentation rate
(ESR), throat culture, chest x-ray, tuberculin test, antistreptolysin O (ASO), serum
immunoglobulins, and biopsy.3,6,7,9-11
If the cause of outbreak is known, treatment is to remove the underlying trigger.
However, in other cases, the use of non-steroidal anti-inflammatories (NSAIDs), potassium
iodide (KI), colchicine, corticosteroids, and rest will help alleviate symptoms.3,6-9 Recurrences
occur more commonly if the etiology is unknown and are estimated in 33-41% of cases.3
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CHAPTER 2
CASE REVIEW
A 21 YO female NCAA-I collegiate soccer goalie presented with complaint of bilateral
elbow and knee joint pain and stiffness along with tender red itchy bumps on the anterior aspect
of her shins that did not follow a dermatome pattern (Figure 1). The previous week, she
complained of flu-like symptoms that resolved within three days but did not see a physician for
symptoms. The current symptoms began approximately three to four days from the onset of joint
pain and swelling. She presented in the athletic training room walking with locked knees and was
unable to actively flex her elbows past 90 degrees due to pain; however, passively she had full
range of motion with mild pain at the end points. A family history of lipoma and breast cancer
exists. Athlete also has a history of anemia diagnosed in 2009, mononucleosis diagnosed in
2009, and multiple diagnosis of streptococcal between 2006 and 2008 that occurred once a year;
she is not on any prescription drugs or oral contraceptives at this time.
The athlete was referred to her family physician for evaluation the day she presented to
the athletic training room. A complete blood count (CBC), metabolic panel, erythrocyte
sedimentation rate (ESR), and antistreptolysin O (ASO) test performed did not show
abnormalities. She was prescribed 200 mg of Celebrex for pain and arthralgia taken once daily
for six days and told the symptoms should resolve in 24-48 hours. HIV/aids were ruled out at this
time due to lack of risky history, Lyme disease because of the rash appearance, and lymphoma
due to normal WBC count. Two days later, the athlete was treated at the emergency room due to
worsening symptoms. She admitted symptoms related to an upper respiratory infection (URI)
two weeks prior to the flu-like symptoms but denied continuing symptoms. She did not see a
physician for any of these symptoms she experienced. Athlete reported stiffness and decreased
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range of motion in both knees and elbows. No signs of joint erythema, warmth, or swelling were
noted at the ER.
An ECG, urine culture, ASO test, and another CBC/ESR were ordered. The ECG showed
normal clear lungs and normal heart size, cloudiness of urine, and a negative strep test was
concluded. The CBC showed low hemoglobin and her ESR was high (Table 1). She was
diagnosed with erythema nodosum, prescribed 800 mg ibuprofen TID PRN for pain and follow
up with her primary physician in one week. At the follow-up, the athlete’s labs revealed a trace
of ketone and increased ESR. The blood culture, urine culture, ANA, rheumatoid arthritis factor,
and strep tests were all within normal limits. Negative RAF ruled out rheumatoid arthritis and
normal ANA tests suggested she did not have lupus.
Test
CBC

Norms
WBC
4.5 - 10 x10E3/uL
3.7 - 5.2
RBC
x10E6/uL
Hg
12 - 16 g/dL
Hct
35 - 47 %
Metabolic
Glucose
65 - 99 mg/dL
Panel
Albumin
3.5 - 5.5 g/dL
Globulin
1.5 - 4.5 g/dL
ESR
0 - 32 mm/hr
ASO
Negative
Urinalysis
Clarity
Clear
Color
Yellow
Specific Gravity
1.005 - 1.030
pH
4.5 - 8
Occult Blood
Negative
Glucose
Negative
Ketones
Negative
Protein
40 - 80
Leukocytes
Negative
ECG
Heart Size
WNL
Lungs
Clear
Spine
Curvature
WNL
RAF
.0 - 13.9
ANA
Negative

First Visit (2-4-13)
6.7

ER Visit (2-6-13)
6.2

Follow-Up (2-11-13)
-

4.38
12.4
36.60%
85
4.1
3
9
Negative
-

4.08
11.9
35.30%
92
4.2
3.2
36
Negative
Cloudy
Dark Yellow
1.032
6.5
Negative
Negative
Trace
30
Moderate
WNL
Clear

53
Negative
Clear
Yellow
1.025
6
Negative
Negative
Trace
Negative
Negative
-

-

Scoliosis
-

11.5
Negative

3

Table 1. Diagnostic Testing
Despite medications prescribed, the athlete’s pain continued to worsen and she was
unable to walk without pain. Swelling appeared around her knees and elbows; however, she no
longer has range of motion limitations. Her family physician diagnosed her with erythema
nodosum and pyrexia; she was prescribed 500 mg of penicillin QID for ten days and 10 mg of
prednisone for 30 days to treat infection and inflammation. Diagnosis of pyrexia could be caused
by the amount of inflammation she presented with and as a side effect of EN. Although the
diagnosis did not change, her treatment plan was altered due to worsening symptoms and no
alleviation of pain. At the fourteen-day follow-up after diagnosis, the athlete complained of
fatigue and joint stiffness; however, the lesions disappeared and left mild scarring (Figure 2).
Lastly, she was prescribed vitamin D for fatigue and advised to follow-up as needed.

Figure 1. Lesions of bilateral anterior
tibia two days after formation

Figure 2. Resolution of lesions
two weeks after diagnosis

Since recovering from diagnosis, athlete has no signs or symptoms of further illnesses. A
follow-up appointment was not needed due to alleviation of symptoms. Lesions resolved two
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weeks and arthralgia persisted for two months after diagnosis. She was back to feeling normal
ten weeks after diagnosis but chose not to return to activity such as leisure running and
intermural soccer until four months after diagnosis (Table 2).
Timeline

Events

1/21/2013

Experienced flu-like and URI symptoms - did not seek medical attention

2/1/2013

Joint pain and swelling
Noticed tender red itchy bumps on bilateral anterior shins with symptoms of
bilateral knee and elbow arthralgia, presented to the ATR and referred to
family physician - CBC, metabolic panel, ESR, and ASO WNL. Prescribed

2/4/2013

200 mg Celebrex; ruled out lymphoma, HIV/aids, and Lyme disease.
ER visit due to worsening symptoms - urinalysis, ASO, CBC, ESR, and
ECG ordered. Low hemoglobin showed in CBC, high ESR, and all other

2/6/2013

tests WNL. Prescribed 800 mg ibuprofen.
Follow-up with PCP - urinalysis showed trace of ketones, elevated ESR,
and negative RAF, blood culture, ANA, and ASO. Prescribed 500 mg

2/11/2013

Penicillin and 10mg Prednisone; ruled out RA and Lupus.
Follow-up with PCP - complaints of fatigue and joint stiffness, lesions

2/25/2013

resolved leaving mild scarring. Prescribed Vitamin D, follow-up as needed.

4/1/2013

Arthralgia symptoms resolved

4/15/2013

Began feeling "normal"

5/27/2013

Returned to activity

Table 2. Timeline of Events
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CHAPTER 3
DIFFERENTIAL DIAGNOSIS
The following is a list of the possible diagnosis and their key symptoms (Refer to Table 3):
Rheumatoid Arthritis12


Joint Pain/Stiffness/Inflammation



Decreased Range of Motion



Fever



Tenderness



Rash



Fatigue



Loss of Appetite



Pain Over Several Joints – Symmetrical Pattern

Rheumatoid arthritis was ruled out to do a negative rheumatoid factor and ANA.
Lymphoma13


Fever



Night Chills



Weight Loss



Rash/Itching



Chest/Lower Back Pain

Lymphoma was ruled out due to lack of symptoms that coincided with the illness.
HIV/aids14


Fatigue



Fever
6



Sore Throat



Swollen Glands



Headache



Muscle/Joint Aches and Pains



Red or Brown Blotches Under Skin

HIV/aids were ruled out due to lack of risky history such as blood transfusion and sexual
behavior.
Erythema nodosum4,6,9


Malaise



Flu-like Symptoms



Joint Pain



Red Tender Bumps on Anterior Tibia (Bilateral)

Erythema nodosum was diagnosis due to symptoms; especially that of the bilateral anterior shin
lesions.
Lupus15


Extreme Fatigue



Headache



Fever



Photosensitivity



Painful/Swollen Joints



Abnormal Blood Clotting



Anemia



Pleurisy
7

Lupus was ruled out after a negative ANA test as well as symptoms did not correspond with
athlete’s complaints.
Lyme disease16 (Figure 3)


Flu-like Symptoms



Joint Pain



Fatigue



Rash (“Bulls-eye” Appearance)

Lyme disease ruled out because athlete does not live in an area of high risk, no history of tick
bite, and her rash does not have the “bulls-eye” appearance.

Figure 3. Lyme disease “Bulls-eye” rash.16

Rheumatoid
Arthritis
Lymphoma
HIV/Aids
Erythema
Nodosum
Lupus
Lyme
Disease

Joint
Pain

Decreased
ROM

Inflammation

Fever

Rash/Lesions

X

X

X

X
X
X

X
X
X

X
X

X

X
X

X

X

X
X
X
X
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Anemia

X
X

Table 3. Differential Diagnosis

Flu-like
Symptoms

X

CHAPTER 4
DISCUSSION
Based on the individual’s previous history of an upper respiratory infection and flu-like
symptoms prior to being diagnosed with EN, these are assumed to be the underlying trigger.
However, due to worsening of symptoms after the athlete was prescribed penicillin, the drug
could also be a possible cause. The athlete states her lesions resolved within two weeks and
symptoms within six weeks of diagnosis. The condition typically resolves on its own in 3-6
weeks. Patients are treated symptomatically with NSAIDs, rest, and elevation.3,7 She was able to
discontinue the prednisone after the first dose. She does not report complications after being
asymptomatic nor has EN recurred.
The athlete’s symptoms were concurrent with those associated with erythema nodosum
including flu-like symptoms, fatigue, arthralgia, and nodules on bilateral anterior tibia. An
extensive history of streptococcal and recent URI along with her demographics predisposed her
to an occurrence of EN. Streptococcal and upper respiratory infections can account for 28-44%
of EN cases with a female to male ratio of 4-5:1 in all cases.3
Several diagnostic tests such as CBC, ANA, urinalysis, and ESR should be performed to
help rule out other possible diagnosis and/or causes of EN (Table 3). A CBC test is a generalized
test of a patient’s health status that can be used to diagnose varying conditions and diseases such
as anemia, infection, leukemia, bone marrow disorders, and lymphoma, to name a few. White
blood cells (WBC), red blood cells (RBC), and platelets are evaluated in a blood sample. Any
elevation or depression of data outside the norm is considered a red flag.17 Antinuclear
antibodies (ANA) test was performed under the suspicion of inflammation that may be due to an
autoimmune illness such as Raynaud’s phenomenon, rheumatoid arthritis, and lupus. ANAs can
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inhibit the body to attack itself mistaking normal proteins as dangerous.18 More commonly used
to screen for lupus, if ANAs are present this may suggest a diagnosis of the disease.19 Physical
features as well as contents of a urinalysis can be evaluated for diagnosis of infection or
inflammation of the kidneys. The specimen shows levels of pH, glucose, ketones, protein, nitrite,
WBC, RBC, bacteria, and concentration. Abnormalities suggested an infection, dehydration,
hematuria (red blood in urine), liver disease, or breakdown of muscle.20 ESR is evaluated with a
blood sample that will indirectly measure the amount of inflammation in the body. This test, if
abnormal, can diagnose some illnesses such as: anemia, lymphoma, lupus, rheumatoid arthritis,
kidney disease, pregnancy, and thyroid disease. However, other testing is advised for abnormal
findings.21
If symptoms do not resolve in 4-6 weeks, other testing may be performed to further
diagnose the cause of EN. Tests should be conducted to rule out sarcoidosis, tuberculosis,
Behcet’s disease, Leprosy, several types of STIs, and other systematic diseases that may lead to
EN. Other causes can be excluded after collecting a biopsy of the infected area; however, a
biopsy is not commonly performed unless the lesions do not regress.3,6,7,9-11 In this case a further
testing was not performed because symptoms were alleviated. The etiology of EN is ruled
uncertain in 37-60% of cases despite medical testing and labs.7
In 15-40% of all cases, EN presents as an early sign of infection, connective tissue
disease and/or inflammatory disorder.6 Of these cases, patients typically present with an elevated
ESR and C-reactive protein levels seen by CBC testing.3,6 The athlete in this case study did not
report development of these conditions after diagnosis of EN; however, she presented with an
elevated ESR that increased from her ER visit to the fourteen-day follow-up. An elevated ESR
and cloudiness of urine sample shows presence of inflammation in the body.20,21 Labs may show
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leukocytosis by a WBC count generally greater than 10,000 per mm.3 Leukocytosis can be
present due to an increase in neutrophil count, lymphocyte count, eosinophilic granulocyte count,
basophilic granulocyte count, or immature cells.22 In this case, the athlete’s WBC count was
below 10,000 per mm, therefore she did not present with leukocytosis.
Patients may also have a higher percentage of reactive oxygen intermediates (ROIs) that
are produced by activated neutrophils in peripheral blood. ROIs contribute to the activity of
phagocytes, regulation of signal transduction and gene expression, and the oxidative damage to
the nucleic acids; proteins; and lipids.23 ROIs utilize effects of the oxidate and create tissue
damage and inflammation. Inflammation is proposed to collect in the anterior shins due to the
combination of arterial supply and gravitational effects of the venous system.7 This
distinguishing location on the shins makes for diagnosis of EN.4
The incident rate of EN is 1-5 cases /100,000 per year.2,4,5 Diagnosis can be caused by
infections such as streptococcal, sarcoidosis, autoimmune disorders, irritable bowel disease, or
medications such as oral contraceptives. In some cases, such as sarcoidosis (disease of unknown
cause leading to inflammation of organs); the presence of EN shows for an improved prognosis.5
Most cases in the United States are diagnosed during the first half of the year when streptococcal
is at its highest incident rate.7
Erythema nodosum is a form of panniculitis, an inflammation of the subcutaneous fat
layer.3-6 EN can be caused by hypersensitivity to antigens such as beta-haemolytic streptococcal.5
Lesions form on the anterior shin and are typically 1-5 cm in diameter. The lesions begin to
flatten as the bumps resolve and heal in a bruise-like appearance.3,5 Patients may experience new
lesions for up to two months, however, they should slowly begin to resolve after two weeks.3,7
Symptoms such as arthralgia may last for up to two years after resolution of lesions.3
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Treatment of EN is symptomatic usually consisting of rest, elevation, and the use of
NSAIDs for alleviation of pain and controlling edema. If caused by a known etiology, such as
oral contraceptives or other medications, the patient should discontinue use. For infections, such
as streptococcal, medications may be prescribed to treat the illness. Potassium iodide (KI) may
be administered if lesions persists longer than six weeks.3,7 The mechanism of KI is to cause
heparin release, which aids in suppressing hypersensitivity reactions.3 However, KI may also
inhibit neutrophil chemotaxis.7
Chronic erythema nodosum can progress based on cases presenting with a lesser degree
of septa thickening and inflammation compared to acute EN. Chronic EN also exhibits
prominent characteristics of phlebitis (inflammation of veins) and extravasated erythrocytes
(blood forced out of vessels), not seen in acute EN. However, some cases are misdiagnosed as
chronic due to the stage of evolution.11
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CHAPTER 5
CONCLUSION
Erythema nodosum is a rare disorder that affects approximately 1-5 per 100,000 people
per year. Typically, seen in the female 25-40 year old population, the cause is usually idiopathic;
however, the most common cause is streptococcal pharyngitis.2-6,11 This case demonstrates the
need for the awareness of a systematic condition that could be present within the athletic
population. With this information, clinicians can better diagnose and treat erythema nodosum
along with an awareness of etiologies causing the condition.
In this case, due to recent diagnosis of URI and flu-like symptoms, they are assumed to
be the cause of EN in this athlete. However, it is uncertain and the cause could have been
idiopathic. Because symptoms worsened after prescribed penicillin the medication may also be a
trigger of the condition. No further investigation was made to determine the actual cause since
lesions resolved within two weeks.
Clinicians should keep in mind EN can be easily diagnosed and treated by the sports
medicine staff. In some instances, EN can be a sign of a more serious condition such as
tuberculosis or sarcoidosis. For this reason it is important for the individual to seek proper
medical diagnostic testing.
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